Want to see GB:4BB full AI Analyst Report?
4BB Stock Chart & Stats
615.00 p
25.00 p(2.04%)
At close: 4:00 PM EST
615.00 p
25.00 p(2.04%)
Day’s Range― - ―
52-Week Range420.00 p - 1,040.00 p
Previous CloseN/A
Volume812.00
Average Volume (3M)999.00
Market Cap
£81.30M
Enterprise Value80.00M
Total Cash (Recent Filing)£17.80M
Total Debt (Recent Filing)£16.50M
Price to Earnings (P/E)―
Beta-0.12
Next Earnings
Sep 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding15,538,518
10 Day Avg. Volume230
30 Day Avg. Volume999
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)9.43
Price to Sales (P/S)56.33
P/FCF Ratio-6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£1,400.00Price Target Upside127.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1
Revenue Forecast (FY)£2.60M
Bulls Say, Bears Say
Bulls Say
Essential Supplier To Gene Therapy Industry4basebio supplies high‑quality plasmid DNA and related materials that are critical inputs for viral vector and mRNA workflows. That positions the company in a structural niche with recurring, program‑linked demand and meaningful switching costs as customers advance from R&D to clinic and commercial stages.
Product + CDMO Service MixThe combination of product sales and contract development/manufacturing services creates multiple, complementary revenue avenues: one‑off and repeat product orders plus fee‑for‑service development work. This mix supports customer stickiness and upsell as partners scale GMP campaigns, improving revenue durability over time.
Historical Revenue ExpansionFundamentals show strong multi‑year top‑line growth off a small base, indicating market demand and commercial traction in earlier years. While 2025 dipped, the historical expansion suggests the company has demonstrated product adoption and addressable market penetration that can support recovery if execution and funding align.
Bears Say
Accelerating Cash BurnConsistent negative operating and free cash flow and accelerating cash burn create a structural funding dependency. Without sustained margin expansion or rapid revenue scale, the company will likely need external capital, increasing dilution risk and limiting ability to invest in capacity or long‑cycle customer projects.
Worsening Leverage And Capital StructureRising debt alongside sharply lower equity weakens financial flexibility and increases fixed obligations. Higher leverage limits the company's ability to weather development timelines or fund capital‑intensive GMP scale‑ups, raising refinancing and covenant risk and increasing the likelihood of costly funding events.
Persistent Deep LossesChronically negative operating and net margins indicate structural profitability challenges: gross profit is being overwhelmed by operating costs. Until revenue scale or structural cost reductions are achieved, sustained losses will impair retained capital, hurt returns, and constrain reinvestment in capacity or R&D.
4basebio UK Societas News
4BB FAQ
What was 4basebio UK Societas’s price range in the past 12 months?
4basebio UK Societas lowest share price was 420.00 p and its highest was 1040.00 p in the past 12 months.
What is 4basebio UK Societas’s market cap?
4basebio UK Societas’s market cap is £81.30M.
When is 4basebio UK Societas’s upcoming earnings report date?
4basebio UK Societas’s upcoming earnings report date is Sep 25, 2026 which is in 87 days.
How were 4basebio UK Societas’s earnings last quarter?
4basebio UK Societas released its earnings results on May 20, 2026. The company reported -0.586 p earnings per share for the quarter, beating the consensus estimate of -0.59 p by 0.004 p.
Is 4basebio UK Societas overvalued?
According to Wall Street analysts 4basebio UK Societas’s price is currently Undervalued.
Does 4basebio UK Societas pay dividends?
4basebio UK Societas does not currently pay dividends.
What is 4basebio UK Societas’s EPS estimate?
4basebio UK Societas’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does 4basebio UK Societas have?
4basebio UK Societas has 15,538,518 shares outstanding.
What happened to 4basebio UK Societas’s price movement after its last earnings report?
4basebio UK Societas reported an EPS of -0.586 p in its last earnings report, beating expectations of -0.59 p. Following the earnings report the stock price went up 7.865%.
Which hedge fund is a major shareholder of 4basebio UK Societas?
Currently, no hedge funds are holding shares in GB:4BB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4basebio UK Societas Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
£1,400.00 (127.64% Upside)
£1,400.00 (127.64% Upside)
Insider Transactions
Bought Shares
Worth £9.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.99%
12-Months-Change
Fundamentals
Return on Equity
-116.21%
Trailing 12-Months
Asset Growth
-33.93%
Trailing 12-Months
Company Description
4basebio UK Societas
4basebio PLC, an enterprise established in 2020 and situated in Cambridge, United Kingdom, is dedicated to the entire process, from conception to delivery, of synthetic DNA and RNA products. The company also provides advanced non-viral vector solutions, with operations spanning the United States, Europe, and other international markets. Their comprehensive offerings encompass research kits, bulk enzymes, various other biological products, as well as crucial licensing and AVV manufacturing services. The company primarily caters to clients within the biotech, pharmaceutical, and contract development and manufacturing organization (CDMO) industries. Notably, the firm adopted its current name, 4basebio PLC, in July 2021, having previously been known as 4basebio UK Societas.
4BB Stock 12 Month Forecast
Average Price Target
1,400.00 p
▲(127.64% Upside)
Technical Analysis
Avacta Group plc
―
Bioventix
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---